Abstract
RESULTS Final results showed that 86% of patients were satisfied or better on a 6-point scale. At week 12, investigators expressed high satisfaction, with a 93% satisfaction rating or better. At weeks 2 and 12, physicians evaluated 98% of patients as improved or better on the Global Aesthetic Improvement Scale. Mild adverse events generally resolved within 2 weeks. Three cases of delayed edema reported 7 to 14 days after treatment resolved without intervention. CONCLUSION Ease of use, minimal postprocedure events, desirable cosmetic outcome, and duration underscore the benefits of CaHA as a safe, efficient, noninvasive treatment option for the aging hand. BioForm Medical Europe commissioned this study and the attendant postmarketing surveillance. BioForm Medical Europe reimbursed each physician a designated sum for each completed patient treatment, including five sets of questionnaires and photos. In return for their participation and completion of the Media Release Form, patients received a maximum of three syringes of BioForm Medical product for treatment of the hands. The individual treating physician determined total cost of treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
